Gilead says Biktarvy demonstrates high rates of viral suppression

Gilead Sciences announced new data from three studies evaluating the efficacy and safety profile of Biktarvy for a broad range of people with HIV, including those with HIV/hepatitis B coinfection and HIV/tuberculosis coinfection. These data and other studies supporting the important role of Biktarvy in the HIV treatment landscape were presented at the 31st Conference on Retroviruses and Opportunistic Infections. “People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs. These studies were conducted to help bridge the unmet HIV treatment gap and better understand the potential of Biktarvy in a broad range of people and communities affected by HIV and their diverse health needs, said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences. “The data presented at CROI contribute to the growing body of long-term evidence for Biktarvy and reinforce Gilead’s commitment to a person-centric approach to HIV treatment research.”